EV/EBITDA Multiple: Silence Therapeutics Inc. (SLN)
This EV/EBITDA price chart for Silence Therapeutics (SLN), whose operations focus on suppressing pathogenic genes via siRNA for genetic therapy clinics, serves as confirmation of the market valuation and currently stands at 0.00. Business growth depends on therapeutic success rather than market cycles, while licensing technologies to pharma behemoths creates a flexible lever for increasing profits.
Comprehensive metric breakdowns and analytics for silence-therapeutics.com (SLN)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Silence Therapeutics|SLN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Silence Therapeutics plc|SLN - Company Cumulative Debt|Debt to Book Capitalization Ratio Silence Therapeutics Corp|SLN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Silence Therapeutics|Quick Liquidity silence-therapeutics.com
- net income and valuation multiples indicators:
SLN - Profit After Tax|Projected Future Earnings Silence Therapeutics|SLN - Market Cap to Earnings|Projected Price to Earnings Silence Therapeutics|SLN - PEG Multiple|Enterprise Value to EBITDA Ratio Silence Therapeutics Corp|SLN - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Silence Therapeutics|SLN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth silence-therapeutics.com|SLN - Net earnings per share growth this year|Net earnings per share growth forecast for next year Silence Therapeutics
- company sales and revenue statistics:
Initial company analysis:SLN (Silence Therapeutics Inc.)
The EV/EBITDA multiple determines the business value of Silence Therapeutics (SLN) relative to its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA trend, an investor assesses the efficiency of the capital-intensive expenditures Silence Therapeutics (SLN) allocates toward developing its RNA platform. Current sentiment is supported by successful clinical trials, which adjusts the asset's market value. The stability of this metric confirms the company's resilience ahead of the launch of the key Phase 3 trials.
Key competitors
EV/EBITDA Multiple TEM (tempus.com)|QGEN - Enterprise Value to EBITDA Ratio|Ionis Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA repligen.com|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio WGS|RARE (Ultragenyx Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BEAM|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|10x Genomics Inc (TXG) - Company Value to EBITDA|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation STOK (Stoke Corp)|BLFS: EV/EBITDA Multiple|wavelifesciences.com (WVE) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Sionna Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA - Company Value to EBITDA|uniQure N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple meiragtx.com MGTX|RGNX: Enterprise Value to EBITDA Ratio|Solid Biosciences Inc - Enterprise Value to Operating Income Before Depreciation Ratio|OCGN: EV/EBITDA Multiple|PACB - Total Company Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio designtx.com (DSGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|Total Company Value to Operating Income Before Depreciation Ratio 4DMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Total Company Value to Operating Income Before Depreciation Ratio Korro Bio Inc. (KRRO)|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|MBIO: EV/EBITDA Multiple|RNAZ - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APDN|EV/EBITDA Multiple BLUE|IPA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC: Enterprise Value to Operating Income Before Depreciation|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|TBIO: EV/EBITDA Multiple|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to EBITDA Ratio UBX
